BCG

World-leading Sleep Expert Dr. Van Der Helm to Deliver Keynote at Insurtech Insights USA, 2024 in New York

Retrieved on: 
пятница, мая 31, 2024
Insurance, UC, Sleep, Accident, PwC, Exercise, Doctor of Philosophy, McKinsey & Company, Safety, Health, Mental health, Cancer, Harvard Medical School, Daylight saving time, BCG, Brain, Importance, Concept, Motivation, AWS, University of California, Berkeley, Pharmaceutical industry

NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- Insurtech Insights USA 2024 , is thrilled to announce a keynote address by Dr. Els van der Helm , a renowned sleep neuroscientist and former McKinsey consultant, on June 5th and 6th at the Javits Centre in New York.

Key Points: 
  • NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- Insurtech Insights USA 2024 , is thrilled to announce a keynote address by Dr. Els van der Helm , a renowned sleep neuroscientist and former McKinsey consultant, on June 5th and 6th at the Javits Centre in New York.
  • Dr. van der Helm will share her groundbreaking insights on the critical role of sleep in enhancing organizational performance and leadership effectiveness.
  • Dr. van der Helm has dedicated her career to improving organizational performance by enhancing the sleep quality of leaders and teams through specialized training.
  • For more information about Insurtech Insights USA 2024 and to register for the conference, please visit here .

Quantis Survey Finds Food & Beverage Executives Fairly Confident in Meeting Sustainability Goals, but Missing Critical Levers in Plans

Retrieved on: 
четверг, мая 30, 2024
Environment, Professional Services, Sustainability, Food, Beverage, Agriculture, Environmental, Social and Governance (ESG), Supply Chain Management, Retail, Organic Food, Natural Resources, BCG, Consumer, Marketing, Habit, Transformation, Recycling

Quantis , a BCG company and leading global sustainability consultancy driving sustainable transformation to align businesses with planetary boundaries, today released its global food and beverage report, Recipe for Transformation .

Key Points: 
  • Quantis , a BCG company and leading global sustainability consultancy driving sustainable transformation to align businesses with planetary boundaries, today released its global food and beverage report, Recipe for Transformation .
  • The report surveyed more than 600 professionals and C-level executives across multiple business functions in the food and beverage industry.
  • Respondents work in large companies within retail, wholesale, consumer packaged goods, commodities and agriculture subsectors of the food and beverage industry.
  • 76% of respondents reported some level of confidence in their sustainability roadmaps and ability to achieve environmental goals by 2030, but action plans are missing critical components for success.

Valar Labs Announces $22 Million Series A to Advance Vesta, First AI Diagnostic Test to Predict Treatment Response in Bladder Cancer, and Catalyze Expansion in Other Cancers

Retrieved on: 
четверг, мая 30, 2024
Technology, Health Technology, Software, Other Health, Biotechnology, Health, Science, Oncology, Artificial Intelligence, Other Science, Uncertainty, Patient, Doctor of Philosophy, General partnership, American Urological Association, AUA, Bladder cancer, H&E, Neoplasm, Disease, Histology, Publication, AI, Cancer, Biomarker, Pear VC, Labs, Valar in Middle-earth, BCG, Abstract, CHAI, Physician, Annual general meeting

Valar Labs , the developer of computational histology AI (CHAI) tests for predicting response to cancer therapies, announced a $22 million Series A financing.

Key Points: 
  • Valar Labs , the developer of computational histology AI (CHAI) tests for predicting response to cancer therapies, announced a $22 million Series A financing.
  • The funding follows Valar Labs’ completion of a recent international, multi-institution validation study and subsequent launch of Vesta, the first AI-based diagnostic test to predict response to first line treatment in bladder cancer.
  • And bladder cancer is only the beginning; we can’t wait to see where they take the technology next.”
    Valar Labs was founded to reduce uncertainty in cancer treatment decisions.
  • “Valar Labs could transform how we approach cancer treatment decisions for a large number of patients today,” said Vineeta Agarwala, MD, PhD, general partner at a16z Bio + Health.

enGene to Present at the Jefferies Global Healthcare Conference

Retrieved on: 
среда, мая 29, 2024
Science, Biotechnology, Research, Oncology, General Health, Health, Genetics, Clinical Trials, BCG, NMIBC, Conference

enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced that Jason Hanson, Chief Executive Officer, will present a corporate overview at the Jefferies Global Healthcare Conference in New York City, on June 5, 2024, at 12:30 p.m.

Key Points: 
  • enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced that Jason Hanson, Chief Executive Officer, will present a corporate overview at the Jefferies Global Healthcare Conference in New York City, on June 5, 2024, at 12:30 p.m.
  • ET.
  • A live webcast of the presentation can be accessed under the Investors section of the enGene website at www.engene.com/presentations and will be archived there for 90 days.

Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast

Retrieved on: 
пятница, мая 17, 2024
Infectious Diseases, FDA, Entertainment, Clinical Trials, Biotechnology, Health, Pharmaceutical, Oncology, Podcast, Partnership, Patient, American Urological Association, News, AUA, Bladder cancer, NK, Bacillus, University, MD Anderson Cancer Center, SII, Research, Cancer, MHC, CIS, BCG, NMIBC, MBBS, Annual general meeting, Vaccine

“The reports that BCG induces loss of MHC has only been recently discovered, resulting in progression of the cancer with cancer immune evasion from the T cells.

Key Points: 
  • “The reports that BCG induces loss of MHC has only been recently discovered, resulting in progression of the cancer with cancer immune evasion from the T cells.
  • These MHC-negative cells are the exact target for natural killer cells which ANKTIVA activates.
  • ANKTIVA, a first-in-class IL-15 receptor agonist, received approval from the FDA on April 22 for the treatment of patients with BCG-unresponsive NMIBC CIS.
  • ANKTIVA’s unique mechanism of action activates the body’s natural killer cells and killer T-cell immune system to attack tumor cells.

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

Retrieved on: 
среда, мая 15, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Axys, Novartis, Celera Corporation, GSK, Ironwood Pharmaceuticals, OncoMed, GSK plc, Regenerative medicine, Genzyme, International business, BIO, University, Patient, Business administration, General partnership, Chairperson, Therapy, Vertex Pharmaceuticals, DDX, NAMS, Acquisition, QLT, BCG, BLA, Pharmacy, Worldwide, Biotechnology Innovation Organization, Management

enGene’s Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson.

Key Points: 
  • enGene’s Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson.
  • “We are pleased to welcome Paul and Wouter to our Board of Directors.
  • “The Company is well-positioned for success, and I look forward to working with the management team to execute its vision.”
    Mr. Joustra said, “I’m thrilled to join enGene’s Board of Directors.
  • Currently Mr. Joustra serves on the board of directors of VectorY Therapeutics and holds a position as a board observer at NewAmsterdam Pharma N.V. (NASDAQ: NAMS).

NatureWorks’ Ingeo PLA Manufacturing Expansion Attracts Record Financing from Krungthai Bank PCL of Thailand

Retrieved on: 
среда, мая 15, 2024
Other Science, Textiles, Research, Packaging, Engineering, Chemicals, Plastics, Manufacturing, Commercial Building & Real Estate, Construction & Property, Environment, Public Relations, Investor Relations, Oil, Gas, Communications, Banking, Alternative Energy, Energy, Professional Services, Other Natural Resources, Science, Agriculture, Natural Resources, Cargill, Farm, PLA, ESG, Hygiene, NatureWorks, PTT Global Chemical, Capsule, Lactic acid, EVP, Krungthai Bank, Climate change, Coffee, Interim, GC, BCG, Biopolymer, Multimedia

NatureWorks , a leading manufacturer of polylactic acid (PLA) biopolymers made from renewable resources, today announced the historic financial support from Krungthai Bank PCL to optimize the capital structure for the new fully-integrated Ingeo™️ PLA manufacturing facility in Thailand.

Key Points: 
  • NatureWorks , a leading manufacturer of polylactic acid (PLA) biopolymers made from renewable resources, today announced the historic financial support from Krungthai Bank PCL to optimize the capital structure for the new fully-integrated Ingeo™️ PLA manufacturing facility in Thailand.
  • The financing from Krungthai Bank, Thailand’s third largest bank, amounting to $350M USD (12,600M Baht Equivalent), is one of the singular largest loans in the bank’s decades-long history and shows confidence in NatureWorks’ market leadership and global economic impact.
  • View the full release here: https://www.businesswire.com/news/home/20240515079862/en/
    Executives from NatureWorks and Krungthai Bank PCL finalized new financing for NatureWorks’ new fully-integrated Ingeo PLA manufacturing facility in Thailand which is on track to open in 2025.
  • To follow NatureWorks as it continues to make strides toward global expansion of bioplastics, visit natureworksllc.com or follow the company on LinkedIn or X (formerly Twitter).

BCG Recognized as a Leader in AI Services by Independent Research Firm

Retrieved on: 
вторник, мая 14, 2024
BCG, AI, Research, Contender, Artificial intelligence, Organization, Forrester Research, Tax, Boston Consulting Group, Medical device

BOSTON, May 14, 2024 /PRNewswire/ -- Boston Consulting Group (BCG) was named a Leader in Artificial Intelligence (AI) Services in a new report by Forrester Research, an independent research firm.

Key Points: 
  • BOSTON, May 14, 2024 /PRNewswire/ -- Boston Consulting Group (BCG) was named a Leader in Artificial Intelligence (AI) Services in a new report by Forrester Research, an independent research firm.
  • The report, titled The Forrester Wave™: AI Services Q4 2024 - The Nine Providers That Matter Most and How They Stack Up, recognized BCG for excelling "at delivering AI with business impact."
  • BCG emerged as one of two vendors identified as a Leader in AI services.
  • "Companies are transitioning from experimentation to transformation and setting bold ambitions for their AI agendas," said Sylvain Duranton, global leader of BCG X.

Women Leaders in Tech Outpace Men Counterparts in Generative AI Adoption

Retrieved on: 
вторник, мая 14, 2024
Risk, Male, Marketing, Engineering, Boston Consulting Group, Trust, Research, BCG, ICS, Work, Workplace, Perception, Synthetic media, Nursing

BOSTON, May 14, 2024 /PRNewswire/ -- Generative AI (GenAI) is proliferating rapidly in the workplace and while women have historically been less likely to adopt new technologies than men have (especially in the early days), a report by Boston Consulting Group (BCG) released today finds that women are generally on par with—or in some cases even slightly outpacing—men peers in terms of GenAI adoption, with notable variations across seniority levels and job functions.

Key Points: 
  • According to the survey, 68% of women in the tech industry said they use a GenAI tool at work more than once a week, compared with 66% of men.
  • Senior women in technical functions (engineering, IT, customer support, sales, and marketing) are ahead of their men counterparts in adopting GenAI.
  • Junior women in technical roles lag their male counterparts by an average of 7 percentage points, a disparity that could exacerbate existing pipeline challenges in numerous tech companies.
  • By comparison, junior men in technical functions are on a par with senior men in those functions and only 13 percentage points behind senior men in nontechnical functions.

OPay Announces Its First Monthly Profit With Nearly 10 Million Daily Active Trading Users

Retrieved on: 
пятница, мая 10, 2024
Partnership, CNBC, Mastercard, CNN, IDG Capital, Investment, Pakistanis, Oracle bone, Source Code Capital, AI, Growth, BCG, Future, SoftBank Vision Fund

SINGAPORE, May 10, 2024 /PRNewswire/ -- OPay, the leading Fintech company focused on emerging markets, today announced its landmark first monthly profitability, with daily active trading users soaring past 9 million and poised to breach the 10 million mark.

Key Points: 
  • SINGAPORE, May 10, 2024 /PRNewswire/ -- OPay, the leading Fintech company focused on emerging markets, today announced its landmark first monthly profitability, with daily active trading users soaring past 9 million and poised to breach the 10 million mark.
  • By April 2024, OPay has established a robust foothold in emerging markets, serving over 50 million users and 1 million merchants, boasting monthly transaction volumes surpassing $12 billion.
  • With daily active trading users approaching the 10 million mark, OPay has also created a significant impact, fostering 400,000 direct and indirect job opportunities.
  • OPay's vision is to serve 1 billion users and 10 million merchants, ultimately creating 3 million job opportunities by 2031.